Tectonic Therapeutic(TECX.US)

Last Updated 19:00:00 ET
longbridge loading
Company Encyclopedia
View More
name
Tectonic Therapeutic
TECX.US
Tectonic Therapeutic, Inc., a biotechnology company, focuses on the discovery and development of therapeutic proteins and antibodies to modulate the activity of G protein-coupled receptors (GPCRs). It develops GEODe technology platform to enable the discovery and development of GPCR-targeted biologic medicines. The company’s lead product is TX45, a Fc-relaxin fusion molecule that activates the RXFP1 receptor, the GPCR target of the hormone, and relaxin. It is also developing TX2100 for the treatment of hereditary hemorrhagic telangiectasia; GPCR modulator bispecific for treating fibrosis; and other GPCR modulators.
1.880 T
TECX.USMarket value -Rank by Market Cap -/-

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    Tectonic Therapeutic to Participate in Investor Conferences

    Tectonic Therapeutic Inc. will participate in two investor conferences in December 2025. The company will hold a fireside chat at the Piper Sandler 37th Annual Healthcare Conference on December 2, 2025, and attend the Evercore 8th Annual Healthcare Conference on December 3, 2025. A live webcast of the fireside chat will be available on the company’s website.

    Reuters·
    US
    TECX
    -3.64%
    Reuters·
    US
    TECX
    -3.64%

    Tectonic Therapeutic, Inc. (NASDAQ:TECX) Receives Consensus Rating of "Moderate Buy" from Brokerages

    Tectonic Therapeutic, Inc. (NASDAQ:TECX) has received a consensus rating of "Moderate Buy" from seven brokerages, with an average 12-month target price of $82.17. Analysts have varied ratings, including one sell, five buy, and one strong buy. Institutional investors hold 62.63% of the stock. The company reported a quarterly EPS of ($1.02), beating estimates by $0.03. Tectonic Therapeutic focuses on therapeutic proteins and antibodies, founded in 2019, headquartered in Watertown, MA.

    Market Beat·
    US
    TECX
    -3.64%
    Market Beat·
    US
    TECX
    -3.64%

    Mizuho Securities Reaffirms Their Buy Rating on Tectonic Therapeutic (TECX)

    Mizuho Securities analyst Uy Ear reiterated a Buy rating on Tectonic Therapeutic, with shares closing at $18.76. The analyst consensus is Strong Buy, with a price target of $85.00, indicating a 353.09% upside. LifeSci Capital also maintained a Buy rating with an $88.00 target. Ear, covering the Healthcare sector, has an average return of -1.3% and a 37.82% success rate on recommended stocks.

    Tip Ranks·
    US
    TECX
    -3.64%
    Tip Ranks·
    US
    TECX
    -3.64%

    Companies Like Tectonic Therapeutic (NASDAQ:TECX) Are In A Position To Invest In Growth

    Tectonic Therapeutic (NASDAQ:TECX) has a cash runway of 4.3 years with $268 million in cash and a cash burn of $63 million annually. Despite not generating revenue, the company is increasing its cash burn by 16% as it invests in growth. Its cash burn represents 17% of its $362 million market capitalization, indicating it could raise additional funds through share issuance. Overall, while there are concerns about rising cash burn, the company's long cash runway and ability to raise funds suggest a positive outlook for shareholders.

    Simplywall·
    US
    TECX
    -3.64%
    Simplywall·
    US
    TECX
    -3.64%

    Tectonic Therapeutic (TECX) Gets a Buy from Mizuho Securities

    Mizuho Securities analyst Uy Ear has reiterated a Buy rating on Tectonic Therapeutic (TECX) with a price target of $85.00. Ear, a 2-star analyst, has an average return of 1.1% and a 37.77% success rate, focusing on the Healthcare sector. Tectonic Therapeutic holds a Strong Buy consensus among analysts, with a price target consensus of $84.83.

    Tip Ranks·
    US
    TECX
    -3.64%
    Tip Ranks·
    US
    TECX
    -3.64%
    © 2026 Longbridge｜Disclaimer